Imatinib mesylate induced erythroderma

Sir, Imatinib is the first molecularly targeted drug developed for the treatment of Chronic myeloid leukemia (CML) and has achieved remarkable success. The drug acts as a dose-dependent inducer of cutaneous adverse reactions with mild reactivity to low or intermediate doses (200-600 mg/day), but sev...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of dermatology, venereology, and leprology Vol. 78; no. 3; p. 408
Main Authors Sanghavi, Swapnil A, Dongre, Atul M, Khopkar, Uday S
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.05.2012
Scientific Scholar
Subjects
Adult
Antineoplastic Agents - adverse effects
Benzamides
Chronic myeloid leukemia
Dermatitis, Exfoliative - chemically induced
Dermatitis, Exfoliative - pathology
Drug dosages
Drug Eruptions - etiology
Drug Eruptions - pathology
Drug therapy
Female
Humans
Imatinib Mesylate
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Medical treatment
Patient outcomes
Piperazines - adverse effects
Pyrimidines - adverse effects
Risk factors
Skin diseases
India
Online AccessGet full text

Cover

More Information
Summary:Sir, Imatinib is the first molecularly targeted drug developed for the treatment of Chronic myeloid leukemia (CML) and has achieved remarkable success. The drug acts as a dose-dependent inducer of cutaneous adverse reactions with mild reactivity to low or intermediate doses (200-600 mg/day), but severe eruptions to high dose (600-1000 mg/day). Severe cutaneous adverse effects such as Stevens Johnson's syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis are uncommon in occurrence.
ISSN:0378-6323
0973-3922
1998-3611
DOI:10.4103/0378-6323.95491